Original Research Article

What should be the PSA threshold value? 2.5 or 4 ng/mL?

Caner Ediz1*, Serhan Cimen2, Serkan Akan1, Muhammed Cihan Temel1, Omer Yılmaz1, Ozlem Koksal3

1Department of Urology, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey
2Department of Urology, Malatya Education and Research Hospital, Malatya, Turkey
3Department of Biostatistics, Sultan Abdulhamid Han Education and Research Hospital, Istanbul, Turkey

Received: 07 January 2019
Accepted: 30 January 2019

*Correspondence:
Dr. Ediz Caner,
E-mail: drcanerediz@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: In this study, author aimed to detect of threshold value of prostate-specific antigen (PSA) to distinguish malignant or benign prostatic lesions in PSA evaluation.

Methods: A total of 61 patients underwent TRUSBP due to high PSA values (2.5-4 ng/mL) at the clinic between 2012-2017. Digital rectal examinations of all patients were normal. Cases with PSA elevation were divided into groups according to the pathology by benign (group 1) or malign (group 2). Author evaluated the predictive factors with the exception of digital rectal examination findings in two groups.

Results: Benign prostate hyperplasia was detected in 35 patients (57.4%) and prostate adenocarcinoma was detected in 26 patients (42.6%). The patient’s age, tPSA, fPSA and PSA density were 62.07 years, 3.55 ng/mL, 0.65 ng/mL and 0.09 ng/mL² in group 1 and 58.54 years, 3.55 ng/mL, 0.74 ng/mL and 0.10 ng/mL² in group 2, respectively. Patient’s age was statistically significant between in two groups (p<0.05). Number of received cores and rate of f/PSA were 12.24-12 and 20.51-18.45% in group 1 and 2, respectively. tPSA, fPSA and PSA density, number of received cores and rate of f/PSA were similar in both groups. In group 2, prostate adenocarcinoma was most common detected with Gleason score 3+3 in 19 of 26 patients (73.1%).

Conclusions: There is a need different assessment to distinguish of malignant lesions from benign lesions. Nowadays, it was impossible to make this difference in patients without digital rectal examination findings, so accepted threshold of PSA should be 2.5 ng/mL.

Keywords: Prostate cancer, Prostate biopsy, Prostate specific antigen

INTRODUCTION

Prostate cancer (PCa) is the most common cancer in elderly men and can be evaluated as highly effective by screening methods. Among these methods, the most commonly used is PSA. PSA is produced by prostatic ductal epithelium and acinar cells and is responsible for the liquefaction of the ejaculate.¹

It is extremely successful in screening and diagnosing, as well as following the PCa. However, it is not specific to cancer tissue. The possibility of high PSA levels due to many causes (infection, catheterization, digital rectal examination etc.) outside of cancer makes it difficult to perform a good cancer screening. 4 ng/mL, which is considered to be a threshold value of PSA, has been replaced by 2.5 ng/mL for the last few years.²
Description of sextant biopsy by Hodge et al, was opened a new era in 1989. Transrectal ultrasound-guided biopsy of the prostate (TRUSBP) has a vital place in the determination of PCa. PCa has been increasing in recent years because PSA has easy accessibility and prostate biopsies can be performed more frequently than in previous years. For this reason, the increase in the frequency of clinically insignificant prostate cancer diagnoses is the basis of the discussion on the PSA threshold value. Author aimed to assess the relationship between PSA (2.5–4 ng/mL) and PCa in patients with benign digital rectal examination (DRE) and determine the cut-off value of PSA in our prostate biopsy cohort.

**METHODS**

**Study population**

Between January 2012 and December 2017, patients with high PSA level in our clinic were retrospectively enrolled. Patient’s Age, grading and findings of digital rectal examination, total (tPSA) and free (fPSA) serum PSA was assessed before biopsy. TRUSBP was then performed in 61 men during the study period. For men with multiple biopsy sessions only the initial session was included in analysis.

The criteria for inclusion in the study were as follows: patients with a PSA value of between 2.5 and 4 ng/mL were included in the study. DRE results were normal. Patients who had an abnormal finding on the digital rectal examination, disease of coagulopathies, urinary tract infections, individuals who had had surgery in the past year and patients who had previous anti-androgen, 5-alfa reductase inhibitory treatment were also excluded from the study.

The patient’s medical records were reviewed, patients with inadequate data were not included the study. Individuals age, grading and findings of digital rectal examination, TRUS calculated PVs with the ellipse method (length X depth X width X π/6), number of received cores, tPSA and fPSA before biopsy, rate of percentage of free to total prostate specific antigen (f/tPSA) and PSA density were noted. PSA density was calculated as total PSA (ng/mL) divided by prostate volume (ml).

One day before the procedure, oral administration of 500-mg levofloxacin and 400-mg etodolac was started and it was continued until the end. The day of biopsy a rectal enema (250 mL) was performed before the biopsy. The procedure was performed while the patient was in the left lateral position with the thighs flexed. The procedure was performed under the guidance of ultrasound device with a 7.5 MHz biplanar probe.

The biopsy was performed on an outpatient basis in a room equipped with all material necessary for emergency intervention. Sedation and anesthesia were not achieved. 10 minutes before the procedure, periprostatic nerve blockade was performed in addition to perianal intrarectal lidocain gel. Injections were delivered at the angle between the seminal vesicle and prostate on each side using 5 cc of 2% lidocaine.

The biopsies were performed by multiple experienced urologists. Standard 12 (both lateral and medial biopsies from the base, medial and apex on the right and left side of the prostatic peripheral zone) or 14 core biopsies was performed for all prostate volumes.

Pathological specimens were reviewed by a single genitourinary pathologist based on the 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. Cases were divided into groups according to the pathology by benign (group 1) or malignant (group 2).

Patients with high grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferations (ASAP) were excluded for the sake of clarity of the results. The detection of clinically significant or clinically insignificant disease by targeted over 12-14 core biopsy was separated with Gleason score.

**Statistical analysis**

All data was analysed with SPSS 16 Windows package (SPSS Inc. Chicago, IL, USA) and Microsoft excel computer programs. In the analysis of the data, the normality hypothesis was first investigated using the Kolmogorov-Smirnov test, followed by Mann-Whitney U test, chi-square as the statistical method. P<0.05 was accepted as statistically significant.

**RESULTS**

Benign prostate hyperplasia was detected in 35 patients (57.4%) and prostate adenocarcinoma was detected in 26 patients (42.6%). The mean ages were statistically significant between two groups: 62.07±8.16 for group 1, 58.54±6.55 for group 2 (p<0.05).

The tPSA level was found 3.55±0.69 ng/mL and 3.60±0.56 ng/mL in group 1 and 2, respectively. Although it was higher in the group 2, there was no statistical difference (p=0.747). The risk of malignancy increases as it correlates with tPSA level. The fPSA level was found 0.65±0.33 ng/mL and 0.74±0.32 ng/mL in group 1 and 2, respectively. Although it was higher in the group 2, there was no statistical difference (p=0.202). The f/tPSA level was found 0.20±0.07% and 0.18±0.01% in group 1 and 2, respectively.

Although it was lower in the group 2, there was no statistical difference (p=0.368). When free psa levels rate decreased, the risk of malignancy increased in coherent with the literature. The PSA density level was found 0.09±0.030 ng/ml² and 0.10±0.04 ng/ml² in group 1 and
2, respectively. Although it was higher in the group 2, there was no statistical difference (p=0.215).

The PSA, f/tPSA and PSA density levels were not statistically significant between two groups (Table 1).

Table 1: Descriptive characteristics and results of patient groups.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1</th>
<th>Group 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.0±8.16</td>
<td>58.5±46.55</td>
<td>0.046*</td>
</tr>
<tr>
<td>PV (ml)</td>
<td>40.0±13.44</td>
<td>37.0±12.99</td>
<td>0.386</td>
</tr>
<tr>
<td>tPSA (ng/mL)</td>
<td>3.55±0.69</td>
<td>3.60±0.56</td>
<td>0.747</td>
</tr>
<tr>
<td>fPSA (ng/mL)</td>
<td>0.65±0.33</td>
<td>0.74±0.32</td>
<td>0.202</td>
</tr>
<tr>
<td>f/tPSA (%)</td>
<td>20.5±7.07</td>
<td>18.45±10.67</td>
<td>0.368</td>
</tr>
<tr>
<td>PSA Density (ng/ml²)</td>
<td>0.09±0.03</td>
<td>0.10±0.04</td>
<td>0.215</td>
</tr>
<tr>
<td>Mean Core (n)</td>
<td>12.24</td>
<td>12</td>
<td>0.23</td>
</tr>
</tbody>
</table>

*p<0.05

In group 2, prostate adenocarcinoma was most common detected with Gleason score 3+3 in 19 of 26 patients (73.1%) (Table 2). Patients with a PSA level of 2.5 to 4 ng/mL have more clinical insignificant prostate cancer and lower Gleason scores. However, high Gleason scores are rarely detected.

Table 2: Distribution of prostate cancer results according to Gleason score.

<table>
<thead>
<tr>
<th>Gleason Score (Group 2)</th>
<th>n (Overall)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>3+3</td>
<td>19</td>
<td>73.1</td>
</tr>
<tr>
<td>3+4</td>
<td>3</td>
<td>11.5</td>
</tr>
<tr>
<td>5+3</td>
<td>1</td>
<td>3.8</td>
</tr>
<tr>
<td>ASAP</td>
<td>3</td>
<td>11.5</td>
</tr>
</tbody>
</table>

**DISCUSSION**

The use of PSA as a serum marker has reformed PCa diagnosis. As an independent variable, PSA is a better predictor of cancer than either DRE or transrectal ultrasound (TRUS). There are no agreed standards defined for measuring PSA. Higher PSA levels indicating greater likelihood of PCa. Numerous men may harbor PCa notwithstanding having low serum PSA. The PSA threshold value is still being discussed up-to-date and there is no clear consensus. With the frequent use of PSA in practice, the diagnosis of PCa is increasing. Clinically insignificant prostate cancer diagnosis is the most important question mark in PSA threshold value. The low PSA threshold value leads to unnecessary biopsy and diagnosis of clinically insignificant prostate cancer. Conversely, a high threshold value leads to the skipping or delay of clinically significant prostate cancer diagnosis.

The current threshold value for tPSA is assumed to be 2.5 ng/mL and varies with age. TPSA thresholds are available in different age groups from 2.5 to 6.5 ng/mL. Another reliable factor for low PSA values is digital rectal examination findings. However, digital rectal examination findings that is specific to prostate cancer is not detected in every patient. Without digital rectal examination, the diagnostic efficacy of PSA variations is extremely important.

Catalona et al, were found the great majority of cancers detected in men with serum PSA levels of 2.6 to 4.0 ng/mL. Free serum PSA measurements may reduce the number of additional biopsies required by the lower PSA cut-off. Thompson et al, were found in patients with lower PSA value (<4 ng/mL) prostate cancer was diagnosed in 15.2% and they said that biopsy-detected prostate cancer, including high-grade cancers, is not rare. Gilbert et al, were found prostate cancer in 27.4% in patients with PSA value (2.5-4 ng/mL) and they have suggested that 2.5 ng/mL may be a more appropriate cutpoint than 4.0 ng/mL. Rashid et al, in 2.5-4 serum PSA range, 28.26% of all malignancy were found, which would be missed if we take cut off value 4. In this study, PCa was detected in 37.7% (23/61) and it was found at a higher rate than the literature. Author think that the lower values of tPSA are more useful in diagnosis of PCa than estimated percentage.

To improve the biopsy/PCa ratio, the consensus recommends fPSA measurement. Cut-off of 1.5 seems to be the most appropriate. Veneziano et al, were found 1.5 value is recommended for patients with PSA levels between 4 and 10 ng/mL. Faria et al, were suggested this value in men with normal DRE and PSA 2.5-4.0 ng/mL in a PCa screening programme. In a similar work, Kitagawa et al, were demonstrated that the f/t PSA ratio was a strong predictor of future cancer detection the probabilities of prostate cancer detection in men with total PSA levels of 2.1-10.0 ng/mL. The differences in probabilities of prostate cancer detection among men with different f/t PSA ratios was found and lower f/t PSA ratios than 15% was more useful for detection of PCa. Liu et al were suggested that routine prostate biopsy should be undertaken if the f/t PSA ratio less than 15% with/without abnormal DRE/TRUS findings in men with PSA levels of 4.0 ng/mL or less. In the cohort, f/t PSA
ratios were higher than literature in both groups. The amount of serum tPSA is a parameter that can be influenced by the prostate volume. uPSA and prostate volume associations were first reported by Veneziano, Pavlica, Querze, Viglietta, Trenta in 1991. Threshold of greater than 0.15 PSA density for benign lesions and less than 0.15 for malign lesions are still being used nowadays.

Yamamoto et al, found to based on PSA density decided prostate biopsy may be further improved, with fewer unnecessary biopsies. Contrary to common belief Pepe et al, was found moreover PSA density accuracy was of poor value in diagnosing PCs in comparison with f/t PSA ratio. In present study, threshold of PSA density could not help us in predicting of prostate cancer.

The relationship between low prostate volume and prostate cancer has been previously described in the literature. The reliability of PSA decreases in patients with prostate volume over 50 mL. Demura et al, was found that increase in prostate volume (PV) is associated with a decrease in size and detectability of cancer lesions resulting in a decrease in biopsy yield. In this study, PV in the PCs detected group was found less than the benign group.

CONCLUSION

Many factors influence prostate biopsy decision. PSA value is one of these factors. Standard tPSA, fPSA, f/tPSA rates and PSA density cutoffs are not sufficient for a proper diagnosis of prostate cancer by ultrasound guided transrectal biopsies. Values of PSA from 2.5 to 4 ng/mL may suggest more benign lesions in advancing age. There is a need different assessment to distinguish of malignant lesions from benign lesions. Nowadays, it was impossible to make this difference in patients without digital rectal examination findings, so accepted threshold of PSA should be 2.5 ng/mL.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

16. Liu X, Tang J, Fei X, Li QY. Prostate-specific Antigen (PSA) density and free to total PSA ratio in diagnosing prostate cancer with prostate-specific
antigen levels of 4.0 ng/ml or less. Iran J Public Health. 2015;44(11):1466-72.

Cite this article as: Ediz C, Cimen S, Akan S, Temel CM, Yilmaz O, Koksak O. What should be the PSA threshold value? 2.5 or 4 ng/mL?. Int J Res Med Sci 2019;7:838-42.